Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study compares the equivalence of hyperpolarized 129Xe MRI to 133Xe scintigraphy for the evaluation of pulmonary function in patients being evaluated for lung transplant.
This is a multicenter, randomized, open-label, cross-over Phase 3 study evaluating hyperpolarized 129Xe gas MRI as compared to 133Xe scintigraphy for the evaluation of pulmonary function. This study will enroll subjects being evaluated for possible lung transplant surgery (either single or bilateral) . Subjects will have both a 129Xe MRI and 133Xe scintigraphy image. The vast differences in technique for obtaining hyperpolarized 129Xe MRI as compared to 133Xe scintigraphy make it impossible to blind study procedures. However, all image interpretation will be performed by personnel blinded to the subject's medical history and all study assessments.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Arm 1 | Active Comparator | Subjects will first undergo hyperpolarized 129Xe MRI followed by 133Xe scintigraphy |
|
| Arm 2 | Active Comparator | Subjects will first undergo 133Xe scintigraphy followed by hyperpolarized 129Xe MRI |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| 129Xe MRI | Drug | Evaluation of pulmonary function |
|
| Measure | Description | Time Frame |
|---|---|---|
| Right lung function | Scan predicted contribution of right lung to overall lung function | 48 hours |
| Measure | Description | Time Frame |
|---|---|---|
| 6 zone analysis | The percentage function contributed by each of the individual 6 lung zones. | 48 hours |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Baseline blood oxygen saturation (SpO2) <90% at rest. For subjects requiring routine supplemental oxygen, SpO2 measurements should be taken with the patient's normal oxygen supplementation.
Subjects that have undergone a prior pneumonectomy surgery to either lung.
Female subjects of childbearing potential with a positive serum pregnancy test at screening, or who are not taking (or not willing to take) acceptable birth control measures through the Follow-up Period. Adequate birth control methods include with a monogamous partner who was sterilized more than 6 months prior to screening, or measures with a Pearl index of <1 used consistently and correctly (including intrauterine devices, or implantable, injectable, oral, or transdermal contraceptives). Women are not considered to be of childbearing potential if they meet at least 1 of the following 2 criteria as documented by the Investigator:
Women who are lactating and insist on breast feeding.
Have received any other investigational therapy within 4 weeks prior to Screening.
Requires anesthesia or heavy sedation to undergo MRI testing. Mild sedation could be acceptable (i.e. a low dose oral acting anxiolytic medication such as alprazolam) as long as, in the opinion of the investigator, the subject meets Inclusion Criteria #4 and #5.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Kenneth P West | Polarean, Inc. | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Duke University Hospital | Durham | North Carolina | 27710 | United States | ||
| University of Virginia |
Not provided
Not provided
Not provided
Not provided
Not provided
| Type | Date | Date Unknown |
|---|---|---|
| Release | Apr 27, 2022 | |
| Reset | May 24, 2022 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Apr 27, 2022 | May 24, 2022 | |||
| Feb 14, 2023 |
Open label crossover study
Not provided
Not provided
Not provided
Not provided
| 133XE scintigraphy | Drug | Evaluation of pulmonary function |
|
|
| Charlottesville |
| Virginia |
| 22908 |
| United States |
| Mar 13, 2023 |
| 4 |
| Feb 1, 2024 | Feb 28, 2024 | 5 |